Global expansion PSI CRO is actively expanding its footprint with new offices in Mexico City, Beijing, Beijing again (China World Tower), and Toronto, plus appointing a Country Manager in Korea. This signals growing demand across the Americas, Asia, and Europe and a need for scalable clinical operations support in multiple regions.

On-time delivery focus The company emphasizes predictable patient enrollment and timely project delivery through rigorous feasibility assessments and MD resources. This presents an opportunity to position PSI CRO for fast-start studies, high churn reduction, and improved study timelines for sponsors with tight NDA/ICF milestones.

Technology platform PSI CRO leverages a proprietary INTELIA platform with VISIONAL study modeling, budgeting, and trial finance tracking, plus a modern tech stack (AWS, Azure, ServiceNow, GitHub, analytics). This enables scalable, data-driven CRO services and potential upsell of modeling, forecasting, and eClinical integration for sponsors seeking transparency and efficiency.

Talent and credibility Low staff turnover, high repeat/referral rates, and initiatives like the CRA Academy indicate a strong, trained workforce and client trust. This suggests opportunities to pitch PSI as a low-risk partner for long-duration programs and complex trials requiring experienced site management and access to a robust talent pool.

Large-scale growth signal Reported revenue exceeding ten billion and a breadth of global offices imply capacity for high-volume, multi-therapeutic trials. Sales opportunities exist to target sponsors planning global Phase II–IV programs, with emphasis on cross-continent enrollment capabilities and standardized, predictable study delivery across regions.